When people living with HIV walk out of prison, they leave with up to a month's worth of HIV medication in their pockets. What they don't necessarily leave with is access to health care or the services that will keep them healthy in the long term.
That is one of the findings of a study published Tuesday in PLoS Medicine. The study was among the first to follow people with HIV from jail or prison back into the community. What they found was that most people — more than half — fell out of care ...
”AMSTERDAM — "If you're on suppressive ART, you are sexually noninfectious. The risk is zero," said Alison Rodger, MD, from University College London, here at the International AIDS Conference 2018.
Rodger made the statement after presenting results from PARTNER2 that showed zero linked transmissions after nearly 77,000 condomless sex acts between serodiscordant gay couples in which the HIV-positive partner had a suppressed viral load.
The findings were greeted by questions, applause, tears, photos, and a handshake from officials from the National Institutes of Health."
Rigardo Rush spends his days at an Atlanta marketing and branding company thinking about designing products that are easy to use. He is literally a “user-experience” expert.
He spends his nights the way many single people do: socializing with friends, going out, and flirting. Because he is Black, gay, and lives in the South, conversations with friends often turn to what they want and need to protect themselves from HIV.
A battle is brewing in the HIV research world about the best way to prevent HIV transmission. On one side are drugs that target the tissue where exposure to the virus occurs — think a gel or douche. On the other is a whole-body approach. Think a pill or a shot.
At the heart of the debate is a tall, square-jawed scientist in wire-rimmed glasses who still carries himself like a military man: Dr. Craig Hendrix. Hendrix’s career has touched every part of the HIV prevention world. He’s analyzed da...
When people started to show up to Dr. William Cooke's primary care office in Austin, Ind., in 2014 with HIV, Cooke knew it was probably related to the region's opioid epidemic. But what he and the rest of the public health community didn't know was who they were missing or how long the HIV outbreak had been going on.
Now they've got a clearer picture — literally. In visualizations published in the Journal of Infectious Diseases, dots and lines define the constellations of Indiana's HIV outbre...
"Patient-centered care is about providers trying to get into the world of the person who is being taken care of — understanding the disease from their perspective," said Mekbib Gemeda, vice president of diversity and inclusion at the Eastern Virginia Medical School in Norfolk.
As care providers, we do that better when we think about the patient's whole world, ask questions, and assume an approach of "cultural humility" by acknowledging what we don't know about a patient's life and preferences, he explained.
Physician leaders know about the potential dangers of opioid prescriptions for pain, and they’re open to new ideas. But while federal agencies encourage that thinking, they’re not as forthcoming with practical support.
Ann Lindsay, MD, cares for people with complex conditions — people with an average of nine conditions and lots of medications. Often, they have pain. And often, when they first enroll in her clinic, they are on an opioid pain reliever.
So when Lindsay and her husband, Alan Glas...
"There's an ethical obligation to ensure that young, black MSM, including those in observational studies, have access to the best possible HIV prevention package, which includes PrEP," she said. "The South can really benefit from the examples of New York City and San Francisco, and it would be wonderful if we had something similar to what Washington State has, something like an [AIDS Drugs Assistance Program] for PrEP. But you have to have the political will."
Tenofovir/emtricitabine (TDF/FTC, Truvada) is effective for preventing HIV transmission in teenagers, but high rates of non-adherence mean that the answer for youth HIV risk can't just be biomedical, according to the findings of a study released this month in the journal JAMA Pediatrics.
"[This study] tells us that [pre-exposure prophylaxis, or] PrEP is safe and should be made available to adolescent men who have sex with men [MSM] who are vulnerable to HIV infection,...
"What we see is that it doesn't matter if you're in a southern or a northern state, in a state that expanded Medicaid or didn't, whether you're in a state that had access to [pre-exposure prophylaxis] or not," Millett told Medscape. "The number of new infections fell when you followed a small set of proven interventions."
What it didn't make clear is that either effective treatment for the partner living with HIV or pre-exposure prophylaxis (PrEP) for the negative partner is sufficient on its own to prevent transmission during baby making.
And HIV-affected families have noticed....